Johnson & Johnson has today announced a lead vaccine candidate for Covid-19 and its commitment to supply one billion vaccines worldwide for emergency pandemic use.
The company expects to initiate Phase 1 human clinical studies of its lead vaccine candidate at the latest by September 2020 and following submission to regulators, anticipates the first batches of vaccine to be available for emergency use in early 2021.
Alex Gorsky, chairman and chief executive officer, Johnson & Johnson, said: “The world is facing an urgent public health crisis and we are committed to doing our part to make a Covid-19 vaccine available and affordable globally as quickly as possible.”
Find out more on the Johnson & Johnson website.